CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

Two abstracts focus on the unique mechanism of action of seladelpar; a third focuses on characterizing patient risk of PBC disease progression

NEWARK, Calif., June 7, 2023 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with significant unmet need, today announced it will make three presentations at the European Association for the Study of the Liver (EASL)'s The International Liver Congress™ 2023. Featured results include novel aspects of the anti-pruritic and anti-fibrotic mechanisms of seladelpar, a first-in-class oral, selective PPARδ agonist, or "delpar," being developed for primary biliary cholangitis (PBC). This year's annual meeting will take place in Vienna, Austria, from June 21-24.